The spectrum of chronic angioedema

Allergy and Asthma Proceedings

Volumn 30, Issue 1, 2009, Pages 11-16

  Banerji, Aleena ^a   Sheffer, Albert L ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Ace inhibitors; Androgens; Angioneurotic; Bradykinin; C1 inhibitor; Hereditary; Idiopathic; Kallikrein; Swelling

Indexed keywords

ADRENALIN; ANDROGEN; ANTIHISTAMINIC AGENT; BRADYKININ ANTAGONIST; CALCIUM ANTAGONIST; COMPLEMENT COMPONENT C1S INHIBITOR; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECALLANTIDE; GINKGO BILOBA EXTRACT; ICATIBANT; KALLIKREIN INHIBITOR; LOOP DIURETIC AGENT; PROSTACYCLIN; SALBUTAMOL; TERBUTALINE;

ACNE; ANGIONEUROTIC EDEMA; BREAST DISEASE; CHOLESTASIS; CLINICAL FEATURE; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DYSPHONIA; GENETIC DISORDER; HIRSUTISM; HUMAN; HYPERTENSION; IDIOPATHIC DISEASE; LIBIDO; LIPOPROTEIN METABOLISM; LIVER NECROSIS; LIVER TUMOR; MENSTRUAL IRREGULARITY; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PATIENT CARE; SEBORRHEA; SIDE EFFECT; WEIGHT GAIN;

ADULT; ANDROGENS; ANGIOEDEMA; CAPILLARY PERMEABILITY; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; COMPLEMENT C1 INHIBITOR PROTEIN; COMPLEMENT C4; FEMALE; HUMANS; MALE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; RISK FACTORS; UNITED STATES;

EID: 63449086961     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2009.30.3188     Document Type: Conference Paper

References (53)

1. Graves R. Clinical lectures on the practice of medicine, 1843. In Classic Descriptions of Disease, 1843, 3rd ed. Springfield, IL: Charles C. Thomas, 623-623, 1955.
2. Quincke HI. Uber akutes umschriebenes hautodem [About an acute described skin edema]. Monatshe Prakt Dermatol 1:129131, 1882.
3. Osler W. Hereditary angio-neurotic oedema. Am J Med Sci 95:362-367, 1888.
4. Donaldson VH, and Evans RR. A biochemical abnormality in hereditary angioneurotic edema: Absence of serum inhibitor of C 1-esterase. Am J Med 35:37-44, 1963.
5. Landerman NS, Webster ME, Becker EL, and Ratcliffe HE. Hereditary angioneurotic edema. II. deficiency on inhibitor for serum globulin permeability factor and/or plasma kallikrein. J Allergy 33:330-341, 1962.
6. Nzeako UC, Frigas E, and Tremaine WJ. Hereditary angioedema: A broad review for clinicians. Arch Intern Med 161: 2417-2429, 2001.
7. Davis AE III. Mechanism of angioedema in first complement component inhibitor deficiency. Immunol Allergy Clin North Am 26:633-651, 2006.
8. Agostoni A, Aygoren-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: Problems and progress. Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 114(suppl 3):S51-S131, 2004.
9. Ziccardi RJ. Activation of the early components of the classical complement pathway under physiologic conditions. J Immunol 126:1769-1773, 1981.
10. Bork K, Meng G, Staubach P, and Hardt J. Hereditary angio- edema: New findings concerning symptoms, affected organs, and course. Am J Med 119:267-274, 2006.
11. Chappatte O, and de Swiet M. Hereditary angioneurotic oedema and pregnancy. Case reports and review of the literature. Br J Obstet Gynaecol 95:938-942, 1988.
12. Nielsen EW, Johansen HT, Hogasen K, et al. Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema. Scand J Immunol 44:185-192, 1996.
13. Nielsen EW, Johansen HT, Hogasen K, et al. Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema. Immunophar-macology 33:359-360, 1996.
14. Sloane DE, Lee CW, and Sheffer AL. Hereditary angioedema: Safety of long-term stanozolol therapy. J Allergy Clin Immunol 120:654-658, 2007.
15. Zuraw BL. Current and future therapy for hereditary angio-edema. Clin Immunol 114:10-16, 2005.
16. Fay A, and Abinun M. Current management of hereditary angio-oedema (C'1 esterase inhibitor deficiency). J Clin Pathol 55:266-270, 2002.
17. Sheffer AL. Hereditary angioedema: Optimal therapy. J Allergy Clin Immunol 120:756-757, 2007.
18. Bork K. Hereditary angioedema with normal C1 inhibitor activity including hereditary angioedema with coagulation factor XII gene mutations. Immunol Allergy Clin North Am 26:709724, 2006.
19. Blanch A, Roche O, Urrutia I, et al. First case of homozygous C1inhibitor deficiency. J Allergy Clin Immunol 118:1330-1335, 2006.
20. Caldwell JR, Ruddy S, and Schur PH, et al. Acquired C1 inhibitor deficiency in lymphosarcoma. Clin Immunol Immuno- pathol 1:39-52, 1972.
21. Jackson J, Sim RB, Whelan A, and Feighery C. An IgG autoan-tibody which inactivates C1-inhibitor. Nature 323:722-724, 1986.
22. Zingale LC, Castelli R, Zanichelli A, Cicardi M. Acquired deficiency of the inhibitor of the first complement component: Presentation, diagnosis, course, and conventional management. Immunol Allergy Clin North Am 26:669-690, 2006.
23. Vleeming W, van Amsterdam JG, Stricker BH, and de Wildt DJ. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf 18:171-188, 1998.
24. Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: The omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial. Am J Hypertens 17:103111, 2004.
25. Byrd JB, Adam A, and Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am 26:725-737, 2006.
26. Sondhi D, Lippmann M, and Murali G. Airway compromise due to angiotensin-converting enzyme inhibitor-induced angio-edema: Clinical experience at a large community teaching hospital. Chest 126:400-404, 2004.
27. Agostoni A, and Cicardi M. Drug-induced angioedema without urticaria. Drug Saf 24:599-606, 2001.
28. Abaci A, Kozan O, Oguz A, et al. Prescribing pattern of anti-hypertensive drugs in primary care units in turkey: Results from the TURKSAHA study. Eur J Clin Pharmacol 63:397-402, 2007.
29. Agah R, Bandi V, and Guntupalli KK. Angioedema: The role of ACE inhibitors and factors associated with poor clinical outcome. Intensive Care Med 23:793-796, 1997.
30. Anderson MW, and deShazo RD. Studies of the mechanism of angiotensin-converting enzyme (ACE) inhibitor-associated an- gioedema: The effect of an ACE inhibitor on cutaneous responses to bradykinin, codeine, and histamine. J Allergy Clin Immunol 85:856-858, 1990.
31. Molinaro G, Cugno M, Perez M, et al. Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. J Pharmacol Exp Ther 303:232-237, 2002.
32. Adam A, Cugno M, Molinaro G, et al. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet 359:2088-2089, 2002.
33. Beltrami L, Zingale LC, Carugo S, and Cicardi M. Angiotensin- converting enzyme inhibitor-related angioedema: How to deal with it. Expert Opin Drug Saf 5:643-649, 2006.
34. Lock RJ, and Gompels MM. C1-inhibitor deficiencies (hereditary angioedema): Where are we with therapies? Curr Allergy Asthma Rep 7:264-269, 2007.
35. Schneider L, Lumry W, Vegh A, et al. Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecal-lantide, a novel kallikrein inhibitor. J Allergy Clin Immunol 120:416-422, 2007.
36. Lefebvre J, Murphey LJ, Hartert TV, et al. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angio-edema. Hypertension 39:460-464, 2002.
37. Frigas E, and Nzeako UC. Angioedema. pathogenesis, differential diagnosis, and treatment. Clin Rev Allergy Immunol 23: 217-231, 2002.
38. Gleich GJ, Schroeter AL, Marcoux JP, et al. Episodic angio-edema associated with eosinophilia. N Engl J Med 310:16211626, 1984.
39. Bochner BS, Friedman B, Krishnaswami G, et al. Episodic eosi-nophilia-myalgia-Kke syndrome in a patient without L-trypto-phan use: Association with eosinophil activation and increased serum levels of granulocyte-macrophage colony-stimulating factor. J Allergy Clin Immunol 88:629-636, 1991.
40. Butterfield JH, Leiferman KM, Abrams J, et al. Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. Blood 79:688 -692, 1992.
41. Tillie-Leblond I, Gosset P, Janin A, et al. Increased interleukin-6 production during the acute phase of the syndrome of episodic angioedema and hypereosinophilia. Clin Exp Allergy 28:491-496, 1998.
42. Butterfield JH, Leiferman KM, and Gleich GJ. Nodules, eosin-ophilia, rheumatism, dermatitis and swelling (NERDS): A novel eosinophilic disorder. Clin Exp Allergy 23:571-580, 1993.
43. Emonet S, Kaya G, and Hauser C. Gleich's syndrome. Ann Dermatol Venereol 127:616-618, 2000.
44. Chikama R, Hosokawa M, Miyazawa T, et al. Nonepisodic angioedema associated with eosinophilia: Report of 4 cases and eview of 33 young female patients reported in Japan. Dermatology 197:321-325, 1998.
45. Mizukawa Y, and Shiohara T. The cytokine profile in a transient variant of angioedema with eosinophilia. Br J Dermatol 144: 169-174, 2001.
46. Shimasaki AK. Five cases of nonepisodic angioedema with eosinophilia. Rinsho Ketsueki 42:639 -643, 2001.
47. Clarkson B, Thompson D, Horwith, et al. Cyclical edema and shock due to increased capillary permeability. Am J Med 29: 193-216, 1960.
48. Fischer R, Ostendorf B, Richter J, and Schneider M. Hypovole-mic shock associated with generalized edema: Paroxysmal non- hereditary angioedema (Clarkson syndrome). Dtsch Med Wochenschr 125:427-428, 2000.
49. Chihara R, Nakamoto H, Arima H, et al. Systemic capillary leak syndrome. Intern Med 41:953-956, 2002.
50. Cau C. Syndrome of increased idiopathic capillary permeability (Clarkson's syndrome). Minerva Med 90:391-396, 1999.
51. Airaghi L, Montori D, Santambrogio L, et al. Chronic systemic capillary leak syndrome. Report of a case and review of the literature. J Intern Med 247:731-735, 2000.
52. Tahirkheli NK, and Greipp PR. Treatment of the systemic capillary leak syndrome with terbutaline and theophylline. A case series. Ann Intern Me. 130:905-909, 1999.
53. Nurnberger W, Heying R, Burdach S, and Gobel U. C1 esterase inhibitor concentrate for capillary leakage syndrome following bone marrow transplantation. Ann Hematol 75:95-101, 1997. C